answer text |
<p>The National Institute for Health and Care Excellence (NICE) evaluates all medicines
referred to its highly specialised technologies (HST) programme, including medicines
for Duchenne muscular dystrophy, consistently in accordance with its published methods
and processes. In 2017, following public consultation, NICE introduced an assessment
of cost-effectiveness into its HST methodology that provides a consistent and transparent
mechanism for evaluating technologies while recognising the need for greater flexibility
in the evaluation of very high cost drugs for the treatment of very rare diseases.</p>
|
|